Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Coronavirus-associated aspergillosis increased 30-day mortality risk

Key clinical point: Therapy for severe COVID-19 infections may increase risk for secondary fungal infections.

Major finding: The 30-mortality rates in patients with COVID-19 was 44% with probable CAPA vs. 19% without.

Study details: Prospective study of 108 patients on mechanical ventilation for COVID-19 in three ICUs in Italy.

Disclosures: The study was performed without external funding. The authors and Dr. Ouellette reported no conflicts of interest. Dr. Brüggemann and coauthors report grants and/or personal fees from companies outside the submitted work.

Citation:

Bartoletti M et al. Clin Infect Dis. 2020 Jul 28. doi: org/10.1093/cid/ciaa1065.